Skip to main content

Table 4 Characteristics of the studies (NACT followed by CCRT)

From: Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer

Author

Year

Location

Sample size

Average age

FIGO stage

NACT regimen

Response rate to treatment

Follow-up

(months)

Survival

Post-NACT (%)

Post-CCRT (%)

3-year PFS

3-year OS

Our trial

2022

China

50

53 (35–68)

IIB-IVA

Weekly cisplatin (40 mg/m2) and paclitaxel (60 mg/m2) for 4 weeks

CR (10.4%)

CR + PR (79.2%)

CR (72.0%)

CR + PR (90.0%)

28

73.6%

83.9%

Singh RB [9]

2013

India

28

51 (35–67)

IIB-IVA

Weekly paclitaxel (60 mg/m2) and carboplatin (AUC = 2) for 6 weeks

CR (7.1%)

CR + PR (67.8%)

CR (85.7%)

CR + PR (92.8%)

12

-

-

McCormack M [10]

2013

UK

46

43 (23–71)

IB-IVA

Weekly paclitaxel (80 mg/m2) and carboplatin (AUC = 2) for 6 weeks

CR (4.5%)

CR + PR (72.7%)

CR (67.4%)

CR + PR (90.7%)

39.1

68%

67%

da Costa Samantha Cabral S [8]

2019

Brazil

55

48 (22–69)

IIB-IVA

Every 3 weeks Cisplatin (50 mg/m2 *d1) and Gemcitabine (1000 mg/m2 *d1, d8) for 3 cycles

CR (12.0%)

CR + PR (80.0%)

CR (56.3%)

CR + PR (92.7%)

31.7

40.9%

60.7%

Gadducci A [31]

2017

Italy

13

55 (35–63)

IIB-IVA

weekly paclitaxel (80 mg/m2) and carboplatin (AUC = 2) for 6 weeks

CR (0%)

CR + PR (76.9%)

CR (58.3%)

CR + PR (91.6%)

12

-

-